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Objectives We sought to conduct a systematic review and meta-analysis of the cardiovascular risk associated with the met-
abolic syndrome as defined by the 2001 National Cholesterol Education Program (NCEP) and 2004 revised Na-
tional Cholesterol Education Program (rNCEP) definitions.
Background Numerous studies have investigated the cardiovascular risk associated with the NCEP and rNCEP definitions of
the metabolic syndrome. There is debate regarding the prognostic significance of the metabolic syndrome for
cardiovascular outcomes.
Methods We searched the Cochrane Library, EMBASE, and Medline databases through June 2009 for prospective observa-
tional studies investigating the cardiovascular effects of the metabolic syndrome. Two reviewers extracted data,
which were aggregated using random-effects models.
Results We identified 87 studies, which included 951,083 patients (NCEP: 63 studies, 497,651 patients; rNCEP: 33
studies, 453,432 patients). There was little variation between the cardiovascular risk associated with NCEP and
rNCEP definitions. When both definitions were pooled, the metabolic syndrome was associated with an in-
creased risk of cardiovascular disease (CVD) (relative risk [RR]: 2.35; 95% confidence interval [CI]: 2.02 to 2.73),
CVD mortality (RR: 2.40; 95% CI: 1.87 to 3.08), all-cause mortality (RR: 1.58; 95% CI: 1.39 to 1.78), myocardial
infarction (RR: 1.99; 95% CI: 1.61 to 2.46), and stroke (RR: 2.27; 95% CI: 1.80 to 2.85). Patients with the meta-
bolic syndrome, but without diabetes, maintained a high cardiovascular risk.
Conclusions The metabolic syndrome is associated with a 2-fold increase in cardiovascular outcomes and a 1.5-fold increase
in all-cause mortality. Studies are needed to investigate whether or not the prognostic significance of the meta-
bolic syndrome exceeds the risk associated with the sum of its individual components. Furthermore, studies are
needed to elucidate the mechanisms by which the metabolic syndrome increases cardiovascular risk. (J Am
Coll Cardiol 2010;56:1113–32) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.05.034P
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Fhe metabolic syndrome affects approximately one-quarter
f North Americans and has become a leading health
oncern due to its link to cardiovascular disease (1). Ever
ince the metabolic syndrome was described by Reaven in
988 (2), a number of definitions have been published by
rganizations including the National Cholesterol Education
rom the *Divisions of Cardiology and Clinical Epidemiology, Jewish General
ospital/McGill University, Montreal, Quebec, Canada; †Faculty of Medicine,
niversity of Montreal, Montreal, Quebec, Canada; ‡Department of Epidemiology,
iostatistics and Occupational Health, McGill University, Montreal, Quebec, Can-
da; §Division of Clinical Epidemiology, McGill University Health Center, Mon-
real, Quebec, Canada; Division of Cardiology, McGill University Health Center,
ontreal, Quebec, Canada; ¶Division of Internal Medicine, McGill University
ealth Center, Montreal, Quebec, Canada; **Division of Internal Medicine, Jewish
eneral Hospital, Montreal, Quebec, Canada; ††Faculty of Pharmacy, Laval Hos-
ital, Quebec Heart and Lung Institute, Sainte-Foy, Quebec, Canada; and the
‡Clinical and Interventional Cardiology, Multidisciplinary Cardiology Department,
aval Hospital, Quebec Heart and Lung Institute, Sainte-Foy, Quebec, Canada. This arogram (NCEP) (3), the International Diabetes Federa-
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thers. Of these, the 2001 Third Report of the NCEP’s
dult Treatment Panel has emerged as the most widely
sed definition, primarily because it provides a relatively
imple approach for diagnosing the metabolic syndrome by
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factors (3,6). Specifically, the
NCEP defines the metabolic
syndrome as having 3 or more of
the following 5 cardiovascular
risk factors: 1) central obesity
(waist circumference: men 102
cm; women88 cm); 2) elevated
triglycerides (150 mg/dl); 3)
diminished high-density lipo-
protein (HDL) cholesterol (men
40 mg/dl; women 50 mg/dl);
4) systemic hypertension (130/
85 mm Hg); and 5) elevated
fasting glucose (110 mg/dl). In
2004, this NCEP definition was
revised (rNCEP) by lowering the
threshold for fasting glucose to
100 mg/dl in concordance with
American Diabetes Association
criteria for impaired fasting glu-
ose (7). Also, thresholds for central obesity were lowered
rom strictly 102 cm in men and 88 cm in women to
reater than or equal to these values. Finally, the rNCEP
efinition includes patients being treated for dyslipidemia,
yperglycemia, or systemic hypertension.
The value of the metabolic syndrome as a predictor of
ardiovascular risk has been met with much debate. In 2005,
he American Diabetes Association and the European
ssociation for the Study of Diabetes issued a joint state-
ent summarizing the issues surrounding the metabolic
yndrome (8). In this statement, they underscore the need to
dentify the cardiovascular risk associated with the metabolic
yndrome. A large number of observational studies have
een carried out to investigate this risk, and there is a need
o synthesize the results of these studies. Two previous
eta-analyses investigating the metabolic syndrome only
ncluded studies published prior to 2005 and did not
nvestigate the rNCEP definition (9,10). Since then, 71
tudies have been published that used the NCEP and
NCEP definitions to investigate the cardiovascular effects
f the metabolic syndrome. Thus, our objective was to carry
ut a systematic review and meta-analysis to estimate the
ardiovascular risk associated with the metabolic syndrome
ccording to the NCEP and rNCEP definitions in the
eneral population and the subpopulations of men, women,
nd patients without type 2 diabetes mellitus.
ethods
ata sources and searches. We systematically searched
he Cochrane Library, EMBASE, and Medline databases
hrough June 2009 using the following key words: all-cause
ortality, cardiovascular risk, cardiovascular disease, cardio-
ascular mortality, fatal myocardial infarction (MI), meta-
Abbreviations
and Acronyms
BMI  body mass index
CI  confidence interval
CVD  cardiovascular
disease
HDL  high-density
lipoprotein
HR  hazard ratio
LDL  low-density
lipoprotein
MI  myocardial infarction
NCEP  National
Cholesterol Education
Program
rNCEP  revised National
Cholesterol Education
Program
RR  relative riskolic syndrome, National Cholesterol Education Program wdult Treatment Panel III, nonfatal MI, revised National
holesterol Education Program Adult Treatment Panel III,
troke, and syndrome X. References from published pro-
pective studies, relevant reviews, and previous meta-
nalyses were hand searched for additional studies not
dentified in the database search.
tudy selection. Eligible studies: 1) were prospective, ob-
ervational studies; 2) stratified patients based on the pres-
nce or absence of the metabolic syndrome using the NCEP
r rNCEP definitions; 3) reported cardiovascular outcomes
nd/or all-cause mortality; 4) reported outcomes as count
ata, or as relative risk (RR) or hazard ratio (HR) with a
orresponding measure of variance; and 5) were published in
he English language. Studies investigating more than 1
ardiovascular outcome or more than 1 definition of the
etabolic syndrome were also eligible for inclusion. Studies
ot meeting these criteria were excluded.
ata extraction. Two reviewers independently extracted
ata using standardized data extraction forms. Disagree-
ents were resolved by consensus or, when necessary, by a
hird reviewer. Reviewers extracted information on study
esign, including the duration of follow-up, the setting, and
he number of participants with and without the metabolic
yndrome according to each definition. Extracted baseline
articipant characteristics included age, sex, mean blood
ressure, body mass index (BMI), cholesterol, triglycerides,
aist circumference, and the prevalence of cardiovascular
isease (CVD), type 2 diabetes mellitus, systemic hyperten-
ion, obesity, and smoking. Reviewers extracted the follow-
ng outcomes: all-cause mortality, CVD, CVD mortality,
I, and stroke. Outcomes data presented as count data,
onadjusted risk estimates (RR or HR) with corresponding
easures of variance, or multivariable adjusted risk esti-
ates were extracted for participants with and without the
etabolic syndrome. The variables included in the multi-
ariable models were also extracted. In addition, when
vailable, outcomes were extracted for different subpopula-
ions, which included men, women, and patients without
ype 2 diabetes mellitus.
ata synthesis and analysis. We synthesized the results of
ncluded studies using random-effects meta-analyses, and
ynthesized results are presented as RRs with corresponding
5% confidence intervals (CIs). Heterogeneity was assessed
sing I2 statistics. We only conducted these meta-analyses
or studies that reported outcomes as count data; studies that
eported outcomes as risk estimates only (HR and RR) were
xcluded from these analyses. In the general population, we
stimated the cardiovascular risk associated with the NCEP,
odified NCEP, the rNCEP, and modified rNCEP defini-
ions of the metabolic syndrome separately. The modified
CEP and modified rNCEP definitions typically used mea-
urements of BMI (typically, BMI 30 kg/m2 or BMI
anging from 25 to 27 kg/m2 for Asian populations) instead
f waist circumference to define central obesity.
We also assessed the cardiovascular risk when all definitions
ere pooled. With the pooled definitions, we determined the
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September 28, 2010:1113–32 The Metabolic Syndrome and Cardiovascular Riskisk in the general population, in men, in women, and in
atients without type 2 diabetes mellitus. Pooled analyses were
onducted for the following 5 outcomes: 1) all-cause mortality;
) CVD; 3) CVD mortality; 4) MI; and 5) stroke. For each
utcome, a meta-analysis was performed to summarize the
verall effects across all relevant studies.
We reported risk estimates (HR and RR) in tables as part
f our systematic review. We classified nonadjusted risk
stimates and risk estimates adjusting exclusively for age
nd/or sex as “least adjusted.” In contrast, risk estimates
djusting for any cardiovascular risk factor (i.e., smoking
tatus, low-density lipoprotein [LDL] cholesterol, and
hysical activity) were classified as “most adjusted.” The
ength of follow-up varied considerably between studies.
herefore, we conducted a sensitivity analysis in which we
tratified studies using the median length of follow-up. In
ddition, funnel plots were constructed and visually assessed
or the possible presence of publication bias. All analyses
ere conducted using MIX software version 1.7 (11,12).
esults
earch results and study inclusion. A total of 3,162
otentially relevant studies were identified in our initial
iterature search (Fig. 1). After screening the abstracts of
hese studies, the full-length papers of 189 studies were
etrieved and assessed for eligibility. Of the retrieved stud-
es, a total of 87 met our inclusion criteria and were included
n our systematic review (Tables 1 to 5). The remaining 102
tudies were excluded either because they did not use the
CEP or rNCEP definitions of the metabolic syndrome to
tratify patients (n  68), they used a cross-sectional study
Figure 1 Flow Diagram of Studies Included in the Systematic R
NCEP  National Cholesterol Education Program; rNCEP  revised National Choleesign (n  31), or they did not report any cardiovascular mutcomes (n  3). No additional studies were identified
hrough our hand search of references from published
tudies, relevant reviews, and previous meta-analyses.
All included studies were published since 2002, had
ample sizes ranging from 76 to 124,513 patients, and had
ollow-up durations ranging from 1.0 to 32.7 years (Online
ables 1 to 4). The prevalence of the metabolic syndrome in
hese studies ranged from 1% in a study of women without
ype 2 diabetes mellitus (13) and 78% in a study of patients
ith type 2 diabetes mellitus (14). There were also varia-
ions in the mean values for each of the 5 components of the
etabolic syndrome: 1) BMI ranged from 22 to 33 kg/m2;
) fasting glucose ranged from 82 to 196 mg/dl; 3) HDL
holesterol ranged from 37 to 64 mg/dl; 4) triglycerides ranged
rom 88 to 199 mg/dl; and 5) systolic blood pressure ranged
rom 117 to 174 mm Hg. Many studies followed specific
ubpopulations, accounting for much of the variability. In
articular, several studies reported outcomes for men (28
tudies; n  172,548), women (24 studies; n  164,768), and
articipants without diabetes (17 studies; n  172,367).
Of the 87 studies (n  951,083) included in our system-
tic review, 43 reported all-cause mortality data (n 
36,864) (Table 1), 19 reported CVD (n  116,202)
Table 2), 38 reported CVD mortality (n  407,350)
Table 3), 12 reported MI (n  29,470) (Table 4), and 26
eported stroke (n  126,633) (Table 5). A total of 38
tudies investigated the NCEP definition (n  345,560)
Online Table 1), and 26 studies investigated the rNCEP
efinition (n  433,808) (Online Table 2). In addition, 25
tudies investigated the modified NCEP definition (n 
52,091) (Online Table 3), and 7 studies investigated the
Education Program.eview
sterolodified rNCEP definition (n 19,624) (Online Table 4).
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The Metabolic Syndrome and Cardiovascular Risk September 28, 2010:1113–32etS Studies Reporting the Incidence of All-Cause MortalityTable 1 MetS Studies Reporting the Incidence of All-Cause Mortality
First Author, Year (Ref. #)* Population n MetS (%)
Follow-Up
(yrs)
Effect
Measure
Risk of All-Cause Mortality†
(95% CI)
All-Cause
Mortality (%)
Least Adjusted Most Adjusted
MetS
Group
Non-MetS
Group
NCEP definition‡
Benetos et al., 2008 (33) Pts without CVD 84,730 9.6 4.7§ HR — 1.63 (1.38–1.93) — —
Butler et al., 2006 (14) General population 3,035 38.5 6.0 RR 1.02 (0.85–1.22) — 14.5 14.2
Men 1,473 — 6.0 RR — — 15.9 19.0
Women 1,562 — 6.0 RR — — 13.4 9.0
Pts with T2DM 461 77.9 6.0 RR 0.71 (0.48–1.06) — 18.1 25.5
Pts without T2DM 2,562 31.6 6.0 RR 0.95 (0.76–1.17) — 12.9 13.6
Dekker et al., 2005 (34) Men 615 19.0 11.0 HR 1.98 (1.28–3.05) — — —
Women 749 25.8 11.0 HR 1.18 (0.72–1.94) — — —
Guize et al., 2007 (35) General population 60,754 10.3 3.6§ HR — 1.79 (1.35–2.38) — —
Hillier et al., 2005 (36) Elderly women with no T2DM 921 27.1 12.2§ HR — 1.30 (1.00–1.70) — —
Hong et al., 2007 (37) Pts with atherosclerosis 14,699 — 9.0§ RR — 1.39 (1.22–1.58) 9.6 5.9
Men with atherosclerosis 6,389 32.4 9.0§ RR — 1.57 (1.31–1.89) 10.2 8.0
Women with atherosclerosis 8,310 29.1 9.0§ RR — 1.22 (1.02–1.47) 9.2 4.3
Hunt et al., 2004 (28) General population 2,107 9.4 12.7§ HR 1.47 (1.13–1.92) — — —
Subjects with CVD 1,947 — 12.7§ HR 1.06 (0.71–1.58) — — —
Katzmarzyk et al., 2005 (38) Nonobese men 7,505 4.7 10.0§ RR — 0.92 (0.53–1.60) 3.98 2.24
Overweight men 9,048 19.8 10.2§ RR — — 3.52 2.21
Obese men 2,620 61.1 10.2§ RR — — 3.44 2.45
Katzmarzyk et al., 2006 (39) Men 20,789 19.7 11.0§ RR 1.46 (1.23–1.74) 1.36 (1.14–1.62) 4.5 2.7
Lakka et al., 2002 (40) Middle-aged men 707 15.0 12.0¶ RR 1.67 (0.95–2.92) 1.67 (0.91–3.08) — —
Langenberg et al., 2006 (41) General population 2,118 — 20.0 HR — 1.43 (1.24–1.65) 71.5 58.8
Men 977 16.9 20.0 HR — 1.44 (1.18–1.76) 74.5 65.8
Women 1,141 15.1 20.0 HR — 1.46 (1.19–1.80) 68.6 53.0
Mancia et al., 2007 (42) General population 2,013 16.2 12.3 HR 2.39 (1.79–3.18) 1.37 (1.02–1.84) 20.2 9.2
Marroquin et al., 2004 (43) Women with CAD 147 42.2 3.5¶ HR — 4.93 (1.02–23.76) 14.5 2.11
Women without CAD 362 34.5 3.5¶ HR — 1.41 (0.32–6.32) 3.2 3.5
Women with T2DM without CAD 340 30.3 3.5¶ RR 2.20 (0.60–8.04) — 7.8 3.5
Monami et al., 2008 (44) Pts with T2DM 1,716 67.1 4.7§ HR 1.36 (1.10–1.69) — — —
Pannier et al., 2008 (45) Normotensive pts 34,577 4.5 4.7§ HR — 1.09 (0.68–1.75) — —
Hypertensive pts 26,447 17.7 4.7§ HR — 1.40 (1.13–1.74) — —
Ramkumar et al., 2007 (46) Pts with moderate CKD 710 48.9 9.0 HR — 1.40 (1.01–1.94) — —
Sundstrom et al., 2006 (47) 70-year-old men 1,221 24.1 32.7 HR 1.58 (1.24–2.01) 1.26 (0.95–1.66) — —
Takeno et al., 2008 (48) Pts with AMI 461 37.3 1.5¶ HR — 1.27 (0.54–3.04) — —
Wang et al., 2007 (49) Elderly without T2DM 1,025 42.7 13.5¶ HR 1.13 (0.93–1.37) 1.08 (0.89–1.31) — —
Elderly men without T2DM — — 13.5¶ HR — 1.08 (0.82–1.42) — —
Elderly women without T2DM — — 13.5¶ HR — 1.08 (0.83–1.40) — —
Wassink et al., 2008 (50) Pts with CV risk factor 3,196 42.6 3.2¶ HR 1.45 (1.17–1.80) 1.43 (1.14–1.78) — —
Zambon et al., 2009 (51) Elderly 2,910 39.0 4.4§ HR 1.30 (1.11–1.54) — — —
Elderly men 1,174 25.6 4.4§ HR 1.26 (0.99–1.60) — — —
Elderly women 1,736 48.1 4.4§ HR 1.33 (1.06–1.68) — — —
Modified NCEP definition#
Chen et al., 2006 (52) Pts with renal disease and ACS 76 76.3 18.1§ RR 2.82 (0.72–11.09) — 31.4 11.1
Feinberg et al., 2007 (53) Pts with ACS, without T2DM 1,060 33.9 1.0 HR — 1.96 (1.18–3.24) 8.9 4.6
Kasai et al., 2006 (54) Pts who underwent PCI 748 42.5 12.0§ HR — 1.34 (0.88–2.05) 13.5 10.5
Levantesi et al., 2005 (55) Pts post-MI 8,245 37.0 3.5 RR 1.15 (0.99–1.33) 1.29 (1.10–1.51) 8.5 7.4
Malik et al., 2004 (56) General population 4,576 37.1 13.3§ HR — 1.40 (1.19–1.66) — —
Subjects with T2DM 4,056 29.0 13.3§ HR — 1.17 (0.96–1.42) — —
Nigam et al., 2006 (57) General population 24,358 13.5 12.6§ HR 1.23 (1.16–1.29) 1.21 (1.14–1.29) — —
Sundstrom et al., 2006 (47) 50-year-old-men 2,322 17.4 32.7 HR 1.67 (1.45–1.93) 1.36 (1.17–1.58) — —
70-year-old-men 1,221 23.1 32.7 HR 1.52 (1.19–1.94) 1.20 (0.90–1.59) — —
Thomas et al., 2007 (58) General population 2,863 17.5 8.5§ RR 3.03 (2.00–4.59) — 7.0 2.3
Revised NCEP definition**
Benetos et al., 2008 (33) Pts without CVD 84,730 16.5 4.7§ HR — 1.32 (1.13–1.53) — —
Davis et al., 2007 (59) Subjects with type 1 diabetes 127 41.7 11.0§ HR — 0.74 (0.32–1.74) — —
Guize et al., 2007 (35) General population 60,754 17.7 3.6§ HR — 1.46 (1.14–1.88) — —
Hildrum et al., 2009 (60) Age 40–59 yrs 3,789 28.0 7.9§ HR 2.06 (1.35–3.13) 2.14 (1.40–3.29) — —
Age 60–74 yrs 1,973 47.0 7.9§ HR 1.10 (0.90–1.36) 1.14 (0.92–1.41) — —
Age 75–89 yrs 986 57.0 7.9§ HR 1.05 (0.88–1.25) 1.05 (0.87–1.26) — —
Huang et al., 2008 (61) Men 58,771 — 8.0 RR 2.09 (1.90–2.30) 1.21 (1.09–1.34) 4.7 2.3
Women 65,742 — 8.0 RR 4.33 (3.85–4.88) 1.30 (1.12–1.49) 4.4 4.1
Pts without T2DM without CVD 117,045 — 8.0 RR — 1.04 (0.94–1.15) 3.1 1.4
Kajimoto et al., 2008 (62) Pts with T2DM who underwent CABG 274 65.3 10.5§ HR 0.84 (0.56–1.27) — — —
Pts without T2DM who underwent CABG 909 40.9 10.5§ HR 1.34 (1.03–1.74) — — —
Katzmarzyk et al., 2006 (39) Men 20,789 26.9 11.0§ RR 1.41 (1.21–1.67) 1.31 (1.11–1.54) 4.2 2.6
Lee et al., 2008 (63) Men 2,787 24.3 14.1§ HR 3.20 (2.50–4.10) 1.40 (1.10–1.80) 16.8 6.3
Women 2,912 21.4 14.1§ HR 5.00 (3.50–6.90) 1.80 (1.30–2.60) 11.7 2.7(continued on next page)
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September 28, 2010:1113–32 The Metabolic Syndrome and Cardiovascular Riskome studies investigated more than 1 cardiovascular out-
ome or more than 1 definition of the metabolic syndrome.
he metabolic syndrome and cardiovascular risk. The
ssociation between the metabolic syndrome and cardiovas-
ular risk was similar for the NCEP and rNCEP definitions
Table 6). Specifically, the metabolic syndrome as defined
y the NCEP definition was associated with an increase in
isk for all-cause mortality (RR: 1.54; 95% CI: 1.29 to 1.84;
2  84%; 95% CI: 73% to 91%) similar to that of the
etabolic syndrome as defined by the rNCEP definition
RR: 1.63; 95% CI: 1.30 to 2.04; I2  95%; 95% CI: 92%
o 97%). There was also little variation in cardiovascular risk
etween the modified NCEP and modified rNCEP defini-
ions compared with the original NCEP definition. Overall,
hen studies investigating all definitions were pooled, the
etabolic syndrome was associated with an increase in the
isk for CVD (RR: 2.35; 95% CI: 2.02 to 2.73; I2  64%;
5% CI: 39% to 79%), CVD mortality (RR: 2.40; 95% CI:
.87 to 3.08; I2  81%; 95% CI: 72% to 88%), all-cause
ortality (RR: 1.58; 95% CI: 1.39 to 1.78; I2  89%; 95%
I: 85% to 92%), MI (RR: 1.99; 95% CI: 1.61 to 2.46; I2
0%; 95% CI: 0% to 73%), and stroke (RR: 2.27; 95% CI:
.80 to 2.85; I2  88%; 95% CI: 82% to 91%) (Table 6,
igs. 2 to 6). The point estimates for cardiovascular risk
ontinuedTable 1 Continued
First Author, Year (Ref. #)* Population n Me
Lopes et al., 2008 (64) Pts with CAD 589
Pts with CAD with T2DM —
Pts with CAD without T2DM —
Mozaffarian et al., 2008 (65) Elderly 4,258
Noto et al., 2008 (66) General population 685
Men —
Women —
Saito et al., 2009 (67) Men 12,412
Women 21,639
Simons et al., 2007 (68) Elderly men 1,233
Elderly women 1,572
Wassink et al., 2008 (50) Pts with CV risk factor 3,196
Pts with CV risk factor without T2DM 2,472
Wen et al., 2008 (69) Elderly men 5,761
Elderly women 4,786
Modified revised NCEP definition#
Hsu et al., 2008 (70) Men 4,888
Women 6,170
Kasai et al., 2008 (71) Pts without T2DM who underwent PCI 450
Niwa et al., 2007 (72) Men 914
Women 1,262
Tanomsup et al., 2007 (73) Men 2,545
Wang et al., 2007 (49) Elderly without T2DM 1,025
Elderly men without T2DM 648
Elderly women without T2DM 377
Studies are listed by category and then alphabetically by author. †Nonadjusted risk estimates and
djusting for any cardiovascular risk factor or component of the metabolic syndrome (i.e., smoking
aving 3 or more of the following 5 cardiovascular risk factors: 1) central obesity (waist circumferen
ipoprotein (HDL) cholesterol (men 40 mg/dl; women 50 mg/dl); and 4) hypertension (130
Median follow-up. #Themodified NCEP andmodified revised NCEP definitions usemeasurements
evised NCEP definition uses a lower cutoff for elevated fasting glucose of 100 mg/dl.
ACS  acute coronary syndrome; AMI  acute myocardial infarction; BMI  body mass index
ardiovascular; CVD cardiovascular disease; HR hazard ratio; MetSmetabolic syndrome; MI
ntervention; Pts  patients; RR  relative risk; T2DM  type 2 diabetes mellitus.ere consistently higher in women compared with men, (specially for all-cause mortality (RR: 1.86; 95% CI: 1.37 to
.52; I2  91%; 95% CI: 85% to 94% for women vs. RR:
.42; 95% CI: 1.16 to 1.74; I2  90%; 95% CI: 81% to 94%
or men).
A small number of studies reported outcomes for patients
ithout type 2 diabetes mellitus. However, even in the
bsence of type 2 diabetes mellitus, the metabolic syndrome
as still associated with an increased risk of CVD mortality
RR: 1.75; 95% CI: 1.19 to 2.58; I2  68%; 95% CI: 8% to
9%), MI (RR: 1.62; 95% CI: 1.31 to 2.01; I2  0%; 95%
I: 0% to 90%), and stroke (RR: 1.86; 95% CI: 1.10 to
.17; I2  89%; 95% CI: 56% to 97%). The confidence
nterval for our assessment of the effect of the metabolic
yndrome on all-cause mortality in this subpopulation was
nconclusive (RR: 1.32; 95% CI: 0.65 to 2.67; I2  87%;
5% CI: 47% to 97%). Finally, there were an insufficient
umber of studies investigating patients with type 2 diabetes
vailable to pool these data.
ensitivity analyses. In sensitivity analyses, we assessed the
otential impact of follow-up duration on our results. These
ensitivity analyses showed that studies with longer
ollow-up times had risk estimates that were similar to those
ith shorter follow-up times. Specifically, in studies with a
ollow-up time that was longer than the median duration
Follow-Up
(yrs)
Effect
Measure
Risk of All-Cause Mortality†
(95% CI)
All-Cause
Mortality (%)
Least Adjusted Most Adjusted
MetS
Group
Non-MetS
Group
2.0 HR — 2.50 (1.15–5.47) — —
2.0 HR — 1.06 (0.38–2.91) — —
2.0 HR — 3.57 (1.38–9.19) — —
15.0 HR 1.31 (1.19–1.43) 1.22 (1.11–1.34) 53.1 47.9
15.0 HR — 1.00 (0.81–1.24) 25.6 23.7
15.0 HR — 0.95 (0.61–1.47) 18.8 19.6
15.0 HR — 1.04 (0.82–1.32) 28.0 28.2
12.3 HR 1.07 (0.94–1.23) 1.06 (0.92–1.23) — —
12.3 HR 1.23 (1.05–1.44) 1.22 (1.03–1.43) — —
16.0 HR 1.60 (1.37–1.86) 1.53 (1.30–1.79) 66.7 52.8
16.0 HR 1.43 (1.23–1.67) 1.35 (1.15–1.59) 51.3 39.4
3.2¶ HR 1.43 (1.15–1.78) 1.40 (1.12–1.75) — —
3.2¶ HR 1.36 (1.05–1.76) 1.34 (1.03–1.74) — —
8.0 RR 1.24 (1.08–1.42) 1.18 (1.02–1.36) — —
8.0 RR 1.27 (1.05–1.54) 1.15 (0.94–1.40) — —
4.7§ HR 1.05 (0.87–1.28) — — —
4.7§ HR 1.46 (1.19–1.80) — — —
12§ HR 0.90 (0.45–1.79) 0.88 (0.42–1.85) — —
12.5§ HR 1.05 (0.60–1.82) 1.13 (0.64–1.98) 17.1 15.3
12.5§ HR 1.24 (0.39–3.95) 1.31 (0.41–4.18) 13.6 6.2
17.0 HR — 1.60 (1.23–2.09) — —
13.5¶ HR 1.10 (0.91–1.33) 1.08 (0.88–1.28) — —
13.5¶ HR — 1.05 (0.80–1.37) — —
13.5¶ HR — 1.09 (0.83–1.43) — —
imates adjusting exclusively for age and/or sex were classified as “least adjusted.” Risk estimates
terol, obesity) were classified as “most adjusted.” ‡The NCEP defines the metabolic syndrome as
n102 cm; women88 cm); 2) elevated triglycerides (150 mg/dl); 3) diminished high-density
m Hg); and 5) elevated fasting glucose (110 mg/dl). §Mean follow-up. Maximum follow-up.
typically BMI30 kg/m2 or BMI27 kg/m2 in Asian populations) to define central obesity. **The
 coronary artery bypass graft; CAD  coronary artery disease; CI  confidence interval; CV 
cardial infarction; NCEP National Cholesterol Education Program; PCI percutaneous coronarytS (%)
52.3
—
—
35.0
22.9
12.4
31.5
—
—
31.1
34.1
50.1
—
45.6
54.4
22.0
28.0
28.7
9.0
1.7
19.3
51.3
—
—
risk est
, choles
ce: me
/85 m
of BMI (
; CABG12.3 years), the risk for CVD mortality associated with the
m
8
w
(
t
t
a
a
f
9
c
2
M
*
a
h
l
f
N
1118 Mottillo et al. JACC Vol. 56, No. 14, 2010
The Metabolic Syndrome and Cardiovascular Risk September 28, 2010:1113–32etabolic syndrome (RR: 2.62; 95% CI: 1.56 to 4.38; I2 
8%; 95% CI: 80% to 93%) was similar to the risk in studies
ith a follow-up time shorter than the median duration
RR: 2.23; 95% CI: 1.74 to 2.86; I2  65%; 95% CI: 30%
o 82%).
Some studies also reported outcomes for patient popula-
etS Studies Reporting the Incidence of CVDTable 2 MetS Studies Reporting the Incidence of CVD
First Author, Year (Ref. #)* Population n MetS (%)
NCEP definition‡
Andreadis et al., 2007 (74) Pts with hypertension 1,007 42.1
Dekker et al., 2005 (34) Men 615 19.0
Women 749 25.8
Jeppesen et al., 2007 (75) General population 2,135 19.2
Resnick et al., 2003 (76) American Indians
without T2DM
2,283 35.0
Sattar et al., 2008 (77) Elderly (age 70–82 yrs)
without T2DM
4,812 27.7
Elderly (age 60–79 yrs)
men without T2DM
2,737 27.2
Wilson et al., 2005 (78) Men 1,549 22.5
Women 1,774 14.9
Modified NCEP definition#
Guzder et al., 2006 (79) Pts with T2DM 428 82.5
Hwang et al., 2009 (80) Men 1,761 21.7
Women 674 11.4
Kokubo et al., 2008 (81) Men 2,492 18.0
Elderly men — —
Women 2,840 20.7
Elderly women — —
Ninomiya et al., 2007 (82) Men 1,050 20.6
Women 1,402 29.9
Schillaci et al., 2004 (83) Hypertensive pts 1,742 34.0
Song et al. 2007 (84) Women with BMI
25 kg/m2
13,526 4.3
Women with BMI
25–29.9 kg/m2
7,834 14.1
Women with BMI
30 kg/m2
4,266 31.4
Takeuchi et al., 2005 (85) Men 780 25.3
Worm et al., 2009 (86) HIV-infected pts 23,202 4.4
Revised NCEP definition**
Ingelsson et al., 2007 (87) Pts without T2DM 1,830 31.8
Liu et al., 2007 (88) General population 30,378 18.2
Meigs et al., 2007 (89) Pts without insulin
resistance
2,104 16.2
Pts with insulin
resistance
699 63.0
Vaccarino et al., 2008 (90) Women received CA
angiography
652 60.0
Wand et al., 2007 (91) HIV-infected pts 881 8.5
Studies are listed by category and then alphabetically by author. †Nonadjusted risk estimates and
djusting for any cardiovascular risk factor or component of the metabolic syndrome (i.e., smoking
aving 3 or more of the following 5 cardiovascular risk factors: 1) central obesity (waist circumferen
ipoprotein (HDL) cholesterol (men40 mg/dl; women50 mg/dl); 4) hypertension (130/85
ollow-up. #The modified NCEP and modified revised NCEP definitions use measurements of BMI (ty
CEP definition uses a lower cutoff for elevated fasting glucose of 100 mg/dl.
CA  coronary artery; HIV  human immunodeficiency virus; other abbreviations as in Table 1.ions with cardiovascular risk factors (systemic hypertension, ttherosclerosis, or a history of CVD). Our sensitivity
nalysis showed that studies of subjects without these risk
actors had risk estimates for CVD mortality (RR: 2.36;
5% CI: 1.79 to 3.1; I2  84%; 95% CI: 75% to 89%)
onsistent with those obtained in our primary analysis (RR:
.40; 95% CI: 1.87 to 3.08; I2  81%; 95% CI: 72%
-Up
s)
Effect
Measure
Risk of CVD† (95% CI)
CVD (%)
Least Adjusted Most Adjusted
MetS
Group
Non-MetS
Group
§ HR 1.75 (1.15–2.66) — 11.8 8.1
 HR 1.91 (1.31–2.79) 1.64 (1.11–2.44) — —
 HR 1.68 (1.11–2.55) 1.17 (0.73–1.87) — —
§ HR — 1.86 (1.39–2.45) — —
¶ HR 1.35 (1.13–1.62) 1.11 (0.79–1.56) — —
¶ HR 1.07 (0.86–1.32) — — —
¶ HR 1.27 (1.04–1.56) — — —
 RR 2.88 (1.99–4.16) — 17.9 4.9
 RR 2.25 (1.31–3.88) — 7.7 2.6
¶ HR 1.27 (0.72–2.23) 2.05 (1.13–3.74) — —
¶ RR 2.02 (1.38–2.95) — 10.0 4.9
¶ RR 5.17 (2.59–10.31) — 15.6 3.0
HR 1.70 (1.23–2.34) 1.75 (1.27–2.41) 12.3 6.5
HR 1.67 (1.16–2.40) 1.73 (1.20–2.48) — —
HR 1.93 (1.35–2.77) 1.90 (1.31–2.77) 9.5 3.2
HR 1.78 (1.19–2.66) 1.70 (1.12–2.59) — —
 HR 1.93 (1.38–2.70) 1.86 (1.32–2.62) 23.2 13.0
 HR 1.68 (1.22–2.33) 1.70 (1.22–2.36) 17.0 7.9
¶ HR — 1.73 (1.25–2.38) — —
§ RR 2.58 (1.88–3.53) 2.40 (1.71–3.37) 7.9 2.2
§ RR 2.92 (2.24–3.79) — 7.1 2.4
§ RR 2.32 (1.71–3.15) — 6.1 2.6
 HR — 2.23 (1.14–4.34) 11.7 6.7
§ RR 2.89 (2.34–3.59) 0.94 (0.69–1.27) — —
¶ RR 2.08 (1.47–2.93) — 10.2 4.9
 HR — 2.01 (1.73–2.33) — —
¶ RR 1.40 (1.00–2.10) 1.30 (0.90–1.90) 10.6 6.1
¶ RR 2.01 (1.28–3.15) — 17.1 8.5
§ RR 2.44 (1.51–3.92) 1.81 (1.10–2.99) — —
 HR — 2.56 (0.86–7.60) — —
imates adjusting exclusively for age and/or sex were classified as “least adjusted.” Risk estimates
terol, obesity) were classified as “most adjusted.” ‡The NCEP defines the metabolic syndrome as
n102 cm; women88 cm); 2) elevated triglycerides (150 mg/dl); 3) diminished high-density
); and 5) elevated fasting glucose (110 mg/dl). §Median follow-up. Maximum follow-up. ¶Mean
BMI30 kg/m2 or BMI27 kg/m2 in Asian populations) to define central obesity. **The revisedFollow
(yr
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iscussion
ur systematic review and meta-analysis was designed to
stimate the cardiovascular risk associated with the meta-
olic syndrome as defined by the NCEP and rNCEP
efinitions. Our literature search was designed to include all
rospective studies investigating the NCEP and rNCEP
efinitions, thereby allowing us to include a large number of
tudies (87 studies; n  951,083).
Overall, the metabolic syndrome was associated with a
-fold increase in risk of CVD, CVD mortality, and stroke,
nd a 1.5-fold increase in risk of all-cause mortality. Thus,
atients with the metabolic syndrome were at higher risk for
ardiovascular outcomes than for all-cause mortality, al-
hough these patients were at elevated risk for either
Figure 2 The Metabolic Syndrome and the Relative Risk for All
I2  89%; 95% confidence interval (CI): 85% to 92%. ACS  acute coronary syndro
MI  myocardial infarction; PCI  percutaneous coronary intervention; Pts  patieutcome compared with those without this syndrome. The hetabolic syndrome was also associated with an approxi-
ate 2-fold increase in risk for MI. There was little
ariation in cardiovascular risk between the NCEP and
NCEP definitions, which principally differ in their thresh-
ld for impaired fasting glucose (110 mg/dl vs. 100
g/dl, respectively). The modified NCEP and modified
NCEP definitions also showed little variation compared
ith the original NCEP definition; these definitions only
iffer in their measurement of central obesity (use of BMI
ersus waist circumference, respectively).
The pathophysiological mechanism by which the meta-
olic syndrome increases cardiovascular risk remains under
ebate (15). Earlier definitions by the World Health Orga-
ization (5) and the European Group for the Study of
nsulin Resistance (16) emphasize the independent role of
nsulin resistance as the underlying component of the
etabolic syndrome. Insulin resistance progresses toward
e Mortality
AD  coronary artery disease; MetS  metabolic syndrome;
R  relative risk; T2DM  type 2 diabetes mellitus.-Caus
me; C
nts; Ryperinsulinemia and hyperglycemia, thus triggering pe-
MetS Studies Reporting the Incidence of CVD MortalityTable 3 MetS Studies Reporting the Incidence of CVD Mortality
First Author, Year (Ref. #)* Population n MetS (%) Follow-Up (yrs) Effect Measure
Risk of CVD Mortality† (95% CI) CVD Mortality (%)
Least Adjusted Most Adjusted MetS Group Non-MetS Group
NCEP definition‡
Benetos et al., 2008 (33) Pts without CVD 84,730 9.6 4.7§ HR — 2.05 (1.28–3.28) — —
Butler et al., 2006 (14) General population 3,035 38.5 6.0 RR 1.37 (0.98–1.92) — 5.13 3.75
Men 1,473 — 6.0 — — — 6.2 5.5
Women 1,562 — 6.0 — — — 4.4 1.9
Pts with T2DM 461 77.9 6.0 RR 0.77 (0.38–1.53) — 7.5 9.8
Pts without T2DM 2,562 31.6 6.0 RR 1.19 (0.79–1.81) — 4.1 3.4
DECODE study, 2007 (92) Men without T2DM age 50–69 yrs 2,790 26.5 10.0 RR 1.48 (1.02–2.14) — 5.55 3.75
Dekker et al., 2005 (34) Men 615 19.0 11.0 HR 2.25 (1.16–4.34) — — —
Women 749 25.8 11.0 HR 0.76 (0.32–1.83) — — —
Hillier et al., 2005 (36) Elderly women with no T2DM 921 27.1 12.2§ HR — 1.60 (1.10–2.30) — —
Hunt et al., 2004 (28) General population 2,107 9.4 12.7§ HR 2.53 (1.74–3.67) — — —
Subjects with CVD 1,947 — 12.7§ HR 2.01 (1.13–3.57) — — —
Katzmarzyk et al., 2005 (38) Nonobese men 7,505 4.7 10.2§ RR 3.74 (1.68–8.32) 1.60 (0.71–3.61) 1.99 0.53
Overweight men 9,048 19.8 10.2§ RR 2.14 (1.35–3.41) — 1.51 0.7
Obese men 2,620 61.1 10.2§ RR 1.33 (0.67–2.63) — 1.56 1.18
Katzmarzyk et al., 2006 (39) Men 20,789 19.7 11.4§ RR 2.03 (1.54–2.69) 1.79 (1.35–2.37) 1.93 0.8
Lakka et al., 2002 (40) Men 707 15.0 11.6§ RR 2.08 (0.93–4.65) 2.27 (0.96–5.36) — —
Langenberg et al., 2006 (41) General population 2,118 — 20.0 HR — 1.50 (1.23–1.83) 38.0 29.1
Men 977 16.9 20.0 HR — 1.28 (0.95–1.71) 32.7 33.7
Women 1,141 15.1 20.0 HR — 1.18 (1.38–2.39) 43.0 25.3
Maggi et al., 2006 (93) Men 1,359 31.4 4.0 HR 3.35 (1.35–8.30) 1.12 (1.09–1.16) — —
Women 1,724 59.5 4.0 HR 1.06 (0.63–1.39) 0.82 (0.56–1.19) — —
Mancia et al., 2007 (42) General population 2,013 16.2 12.3 HR 3.27 (1.97–5.41) 1.71 (1.02–2.85) 7.3 2.4
Monami et al., 2008 (44) Pts with T2DM 1,716 67.1 4.7§ HR 1.82 (1.24–2.68) — — —
Solymoss et al., 2009 (94) Pts with 50% stenosis of CA 876 53.0 12.6§ HR 1.43 (0.97–2.11) 1.42 (0.96–2.10) — —
Sundstrom et al., 2006 (47) 70-year-old men 1,221 24.1 32.7 HR 2.01 (1.41–2.85) 1.43 (0.95–2.17) — —
Wang et al., 2007 (49) Elderly without T2DM 1,025 42.7 13.5¶ HR 1.43 (1.12–1.84) 1.35 (1.05–1.74) — —
Elderly men without T2DM — — 13.5¶ HR — 1.43 (1.00–2.03) — —
Elderly women without T2DM — — 13.5¶ HR — 1.27 (0.89–1.82) — —
Wassink et al., 2008 (50) Pts with CV risk factor 3,196 42.6 3.2¶ HR 1.71 (1.31–2.24) 1.65 (1.25–2.17) — —
Zambon et al., 2009 (51) Elderly 2,910 39.0 4.4§ HR 1.36 (1.03–1.78) — — —
Elderly men 1,174 25.6 4.4§ HR 1.51 (0.98–2.33) — — —
Elderly women 1,736 48.1 4.4§ HR 1.27 (0.90–1.79) — — —
(continued on next page)
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ContinuedTable 3 Continued
First Author, Year (Ref. #)* Population n MetS (%) Follow-Up (yrs) Effect Measure
Risk of CVD Mortality† (95% CI) CVD Mortality (%)
Least Adjusted Most Adjusted MetS Group Non-MetS Group
Modified NCEP definition#
Chen et al., 2006 (52) Pts with renal disease and ACS 76 73.7 18.2§ — — — 24.0 0.0
de Simone et al., 2007 (95) Hypertensive subjects 8,243 19.3 10.0 HR — 1.73 (1.38–2.17) — —
Kasai et al., 2006 (54) Pts who underwent PCI 748 28.7 12§ RR 2.70 (1.28–5.70) — 6.3 2.3
Malik et al., 2004 (56) General population 4,576 37.1 13.3§ HR — 1.82 (1.40–2.37) — —
Subjects with T2DM 4,056 29.0 13.3§ HR — 1.65 (1.10–2.47) — —
Nigam et al., 2006 (57) General population 24,358 13.5 12.6§ HR 1.26 (1.19–1.35) 1.22 (1.14–1.31) — —
Nakatani et al., 2007 (96) Japanese pts with AMI 3,858 42.7 2.0¶ HR — 1.08 (0.62–1.90) — —
Sundstrom et al., 2006 (47) 50-year-old men 2,322 17.4 32.7 HR 2.21 (1.82–2.68) 1.59 (1.29–1.95) — —
70-year-old men 1,221 23.1 32.7 HR 2.11 (1.49–3.00) 1.55 (1.02–2.35) — —
Thomas et al., 2007 (58) General population 2,863 17.5 8.5§ RR 6.12 (2.99–12.51) — 3.4 0.6
Revised NCEP definition**
Benetos et al., 2008 (33) Pts without CVD 84,730 16.5 4.7§ HR — 1.64 (1.08–2.50) — —
Davis et al., 2007 (59) Subjects with type 1 diabetes 127 41.7 11.0§ HR 1.37 (0.40–4.74) — — —
Hildrum et al., 2009 (60) Age 40–59 yrs 3,789 28.0 7.9§ HR 3.97 (2.00–7.88) 3.95 (1.96–7.97) — —
Age 60–74 yrs 1,973 47.0 7.9§ HR 1.07 (0.82–1.39) 1.09 (0.83–1.43) — —
Age 75–89 yrs 986 57.0 7.9§ HR 1.12 (0.90–1.40) 1.11 (0.89–1.39) — —
Huang et al., 2008 (61) Men 58,771 — 8.0 RR 3.17 (2.56–3.93) 1.77 (1.40–2.24) 1.2 0.4
Women 65,742 — 8.0 RR 7.46 (5.55–10.02) 1.69 (1.19–2.42) 1.0 0.1
Pts without T2DM and CVD 117,045 — 8.0 RR — 1.68 (1.32–2.16) 0.7 0.2
Hunt et al., 2007 (97) Men without T2DM 1,940 15.6 15.5§ RR 3.38 (1.95–5.85) — 5.1 1.5
Women without T2DM 2,532 19.4 15.5§ RR 1.81 (1.17–2.81) — 7.2 4.0
Kajimoto et al., 2008 (62) Nondiabetic pts who had CABG 909 40.9 10.5§ HR 2.31 (1.36–3.92) — — —
Diabetic pts who had CABG 274 65.3 10.5§ HR 0.75 (0.41–1.36) — — —
Katzmarzyk et al., 2006 (39) Men 20,789 26.9 11.4§ RR 1.89 (1.44–2.47) 1.67 (1.27–2.19) 1.7 0.8
Lee et al., 2008 (63) Men 2,787 24.3 14.1§ HR 6.70 (4.30–10.40) 3.00 (1.90–4.80) 8.1 1.4
Women 2,912 21.4 14.1§ HR 7.40 (4.00–13.80) 2.10 (1.10–4.00) 4.3 0.7
Mozaffarian et al., 2008 (65) Elderly 4,258 35.0 15.0 RR 1.51 (1.29–1.76) — — —
Noto et al., 2008 (66) General population 685 22.9 15.0 HR 1.33 (0.96–1.83) — 10.6 7.8
Men — 12.4 15.0 HR 1.45 (0.83–2.52) — 11.8 7.6
Women — 31.5 15.0 HR 1.31 (0.88–1.93) — 10.2 7.9
Saito et al., 2009 (67) Men 12,412 — 12.3¶ HR 1.61 (1.16–2.23) 1.41 (0.99–2.02) — —
Women 21,639 — 12.3¶ HR 1.46 (1.00–2.13) 1.44 (0.98–2.11) — —
Wassink et al., 2008 (50) Pts with CV risk factor 3,196 50.1 3.2¶ HR 1.69 (1.28–2.22) 1.61 (1.22–2.14) — —
Pts with CV factor without T2DM 2,472 — 3.2¶ HR 1.55 (1.12–2.14) 1.49 (1.07–2.08) — —
Wen et al., 2008 (69) Elderly men 5,761 45.6 8.0 RR 1.70 (1.28–2.23) 1.45 (1.07–1.96) — —
Elderly women 4,786 54.4 8.0 RR 1.86 (1.21–2.84) 1.66 (1.05–2.60) — —
Modified revised NCEP definition#
Espinola-Klein et al., 2007 (98) Pts with CAD 811 43.0 6.7¶ HR — 2.50 (1.60–3.80) 18.4 7.4
Hsu et al., 2008 (70) Men 4,888 22.0 4.7§ HR — 1.40 (0.96–2.04) — —
Women 6,170 28.0 4.7§ HR — 1.85 (1.25–2.73) — —
Niwa et al., 2007 (72) Men 914 9.0 12.5§ HR 1.67 (0.65–4.34) 1.84 (0.68–4.96) 6.1 3.7
Women 1,262 1.7 12.5§ HR 1.12 (0.15–8.39) 1.31 (0.17–9.96) 4.5 2.03
Wang et al., 2007 (49) Elderly without T2DM 1,025 51.3 13.5¶ HR 1.37 (1.07–1.77) 1.31 (1.02–1.69) — —
Elderly men without T2DM 648 — 13.5¶ HR — 1.32 (0.93–1.87) — —
Elderly women without T2DM 377 — 13.5¶ HR — 1.29 (0.89–1.87) — —
*Studies are listed by category and then alphabetically by author. †Nonadjusted risk estimates and risk estimates adjusting exclusively for age and/or sex were classified as “least adjusted.” Risk estimates adjusting for any cardiovascular risk factor or component of the
metabolic syndrome (i.e., smoking, cholesterol, obesity) were classified as “most adjusted.” ‡The NCEP defines the metabolic syndrome as having 3 or more of the following 5 cardiovascular risk factors: 1) central obesity (waist circumference: men 102 cm; women 88
cm); 2) elevated triglycerides (150mg/dl); 3) diminished high-density lipoprotein (HDL) cholesterol (men40mg/dl; women50mg/dl); 4) hypertension (130/85mmHg); and 5) elevated fasting glucose (110mg/dl). §Mean follow-up. Maximum follow-up. ¶Median
follow-up. #The modified NCEP and modified revised NCEP definitions use measurements of BMI (typically BMI 30 kg/m2 or BMI 27 kg/m2 in Asian populations) to define central obesity. **The revised NCEP definition uses a lower cutoff for elevated fasting glucose
of  100 mg/dl.
Abbreviations as in Tables 1 and 2.
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MetS Studies Reporting the Incidence of MITable 4 MetS Studies Reporting the Incidence of MI
First Author, Year (Ref. #)* Population n MetS (%) Follow-Up (yrs) Effect Measure
Risk of MI† (95% CI) MI (%)
Least Adjusted Most Adjusted MetS Group Non-MetS Group
NCEP definition‡
Butler et al., 2006 (14) General population 3,035 38.5 6.0§ HR — 1.51 (1.12–2.05) 9.1 5.7
Men 1,473 — 6.0§ HR — — 12.1 8.1
Women 1,562 — 6.0§ HR — — 6.8 3.1
Pts with T2DM 461 77.9 6.0§ RR 0.95 (0.52–1.74) — 11.1 11.8
Pts without T2DM 2,562 31.6 6.0§ RR 1.51 (1.11–2.04) — 8.2 5.4
Girman et al., 2004 (99) Pts without T2DM 1,991 20.6 5.4¶ HR 1.49 (1.21–1.83) — — —
Pts without T2DM 3,188 46.0 5.0§ HR 1.49 (0.99–2.25) — — —
Holvoet et al., 2004 (100) Elderly 3,033 37.8 5.0§ RR 1.91 (1.35–2.72) 1.97 (1.35–2.86) 5.6 2.9
Solymoss et al., 2009 (94) Pts with 50% stenosis of CA 204 53.0 12.6¶ HR 2.36 (1.00–5.57) 2.25 (0.93–5.43) — —
Takeno et al., 2008 (48) Pts with AMI 461 37.3 1.5 HR — 0.84 (0.23–2.70) — —
Thorn et al., 2009 (101) Pts with type 1 diabetes 2,474 — 5.7 HR 2.61 (1.90–3.59) 1.85 (1.32–2.59) — —
Wassink et al., 2008 (50) Pts with CV risk factor 3,196 42.6 3.2 HR 1.54 (1.16–2.04) 1.61 (1.21–2.15) — —
Modified NCEP definition#
Chen et al., 2006 (52) Pts with renal disease and ACS 76 76.3 18.1¶ HR — — 16.0 0.0
Kasai et al., 2006 (54) Pts who underwent PCI 748 28.7 12¶ RR 1.35 (0.70–2.61) — 5.4 4.0
Kokubo et al., 2008 (81) Men 2,492 18.0 — HR 2.09 (1.30–3.37) 2.12 (1.31–3.43) 5.8 2.6
Women 2,840 20.7 — HR 2.68 (1.41–5.10) 2.77 (1.44–5.32) 3.6 0.8
Revised NCEP definition**
Nilsson et al., 2007 (102) Pts without T2DM 5,047 20.7 10.7¶ RR 1.99 (1.47–2.69) — 5.8 2.9
Men without T2DM 3,008 26.0 10.7¶ RR 1.87 (1.30–2.67) — 8.7 4.6
Women without T2DM 2,039 17.0 10.7¶ RR 1.48 (0.82–2.68) — 2.7 1.8
Noto et al., 2008 (66) General population 685 22.9 15.0§ HR — 1.91 (1.28–2.83) 7.5 3.9
Wassink et al., 2008 (50) Pts with CV risk factor 3,196 50.1 3.2 HR 1.60 (1.20–2.14) 1.68 (1.25–2.26) — —
Pts with CV factor without T2DM 2,472 — 3.2 HR 1.57 (1.12–2.20) 1.65 (1.16–2.34) — —
*Studies are listed by category and then alphabetically by author. †Nonadjusted risk estimates and risk estimates adjusting exclusively for age and/or sex were classified as “least adjusted.” Risk estimates adjusting for any cardiovascular risk factor or component of the
metabolic syndrome (i.e., smoking, cholesterol, obesity) were classified as “most adjusted.” ‡The NCEP defines the metabolic syndrome as having 3 or more of the following 5 cardiovascular risk factors: 1) central obesity (waist circumference: men 102 cm; women 88
cm); 2) elevated triglycerides (150mg/dl); 3) diminished high-density lipoprotein (HDL) cholesterol (men40mg/dl; women50mg/dl); 4) hypertension (130/85mmHg); and 5) elevated fasting glucose (110mg/dl). §Maximum follow-up. Median follow-up. ¶Mean
follow-up. #The modified NCEP and modified revised NCEP definitions use measurements of BMI (typically BMI 30 kg/m2 or BMI 27 kg/m2 in Asian populations) to define central obesity. **The revised NCEP definition uses a lower cutoff for elevated fasting glucose
of 100 mg/dl.
Abbreviations as in Tables 1 and 2.
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roduction of very low-density lipoprotein also increases,
eading to hypertriglyceridemia, low HDL cholesterol, ele-
ated apolipoprotein B, elevated small LDL cholesterol, and
onsequently, atherosclerosis. As a result of these lipid
mbalances, individuals with the metabolic syndrome typi-
ally exhibit a prothrombotic and proinflammatory state
15,17). More recent definitions by the NCEP (3), rNCEP
7), and the International Diabetes Federation (4) empha-
ize central obesity as the underlying component. Adipo-
ytes secrete mediators including TNF-, leptin, adiponec-
in, and resistin, which lead to insulin resistance. In these
efinitions, it is postulated that central obesity causes
ystemic hypertension and dyslipidemia independently and
hrough the induction of insulin resistance.
Regardless of which definition is used, insulin resistance
nd central obesity are postulated to be the key components
f the metabolic syndrome, and both lead to glucose
ntolerance and dysglycemia. Consequently, even a small
hange in the fasting glucose threshold may have an
mportant impact on the associated cardiovascular risk. For
his reason, there has been considerable debate over the
mpact of lowering the fasting glucose threshold from 110
o 100 mg/dl. We therefore carried out a meta-analysis of
he cardiovascular risk associated with the rNCEP defini-
Figure 3 The Metabolic Syndrome and the Relative Risk for CV
I2  64%; 95% CI: 39% to 79%. BMI  body mass index; CVD  cardiovascular dion in addition to the original NCEP definition. sPrevious meta-analyses showed that the metabolic syn-
rome was associated with higher cardiovascular risk in
omen relative to men (9,10). In our meta-analysis, the
oint estimates for cardiovascular risk were consistently
igher in women compared with men. However, patient-
evel data are needed to confirm this finding. The mecha-
isms explaining a potentially higher cardiovascular risk in
omen with the metabolic syndrome are unclear; however,
everal theories have been postulated (18–20). First, central
diposity tends to be more pronounced in women post-
enopause than in men, and thus may be linked to a higher
isk of cardiovascular disease (18). Second, the cholesterol
rofile is different in women compared with men. HDL
holesterol decreases post-menopause and LDL cholesterol
ncreases post-menopause, with LDL particles becoming
enser, and therefore, more atherogenic (19). Third, there is
vidence that elevated triglycerides are more highly associ-
ted with coronary artery disease in women than in men. In
meta-analysis, it was shown that an increase in triglycer-
des of 18 mg/dl was associated with a 76% increased
ardiovascular risk in women compared with a 32% in-
reased risk in men (20). Finally, several studies have
uggested a number of other unique risk factors that may be
esponsible for a stronger association between the metabolic
; other abbreviations as in Figure 2.D
iseaseyndrome and cardiovascular risk in women. These risk
MetS Studies Reporting the Incidence of StrokeTable 5 MetS Studies Reporting the Incidence of Stroke
First Author, Year (Ref. #)* Population n MetS (%) Follow-Up (yrs) Effect Measure
Risk of Stroke† (95% CI) Stroke (%)
Least Adjusted Most Adjusted MetS Group Non-MetS Group
NCEP definition‡
Boden-Albala et al., 2007 (103) General population 3,297 44.0 6.4§ HR — 1.50 (1.10–2.20) — —
Men 1,220 38.0 6.4§ HR — 1.10 (0.60–1.90) — —
Women 2,077 48.0 6.4§ HR — 2.00 (1.30–3.10) — —
Hsia et al., 2003 (104) Women with angiographic disease 397 61.2 2.8§ RR 1.90 (0.52–6.91) — 3.7 1.9
McNeill et al., 2005 (105) Men 6,881 23.7 11.0§ RR 1.28 (0.87–1.89) — 2.2 1.7
Women 5,208 22.7 11.0§ RR 5.45 (3.92–7.59) — 7.4 1.4
Qiao et al., 2009 (106) Men without CAD and T2DM 4,041 — 21.0 HR 1.30 (0.92–1.83) — — —
Women without CAD and T2DM 3,812 — 21.0 HR 2.30 (1.36–1.90) — — —
Solymoss et al., 2009 (94) Pts with 50% stenosis of CA 876 53.0 12.6§ HR 1.67 (1.18–2.37) 1.68 (1.18–2.39) — —
Thorn et al., 2009 (101) Pts with type 1 diabetes 2,474 — 5.7¶ HR 1.94 (1.25–3.02) 1.51 (0.94–2.44) — —
Vlek et al., 2008 (107) Hypertensive pts without T2DM 1,815 42.7 3.9§ HR 1.36 (0.85–2.16) — — —
Wang et al., 2008 (108) Elderly without T2DM 991 42.1 13.8¶ HR 1.62 (1.17–2.24) — — —
Wassink et al.,2008 (50) Pts with CV risk factor 3,196 42.6 3.2¶ HR 1.66 (1.10–2.49) 1.73 (1.13–2.65) — —
Modified NCEP definition#
Chen et al. 2006 (109) Men 725 45.5 10.4§ HR 5.80 (2.00–16.50) — 9.1 1.0
Women 831 58.7 10.4§ HR 2.50 (0.70–8.40) — 7.7 0.7
Chien et al., 2007 (110) General population 3,507 24.2 9.0¶ HR — 2.05 (1.45–2.91) — —
Hwang et al., 2009 (80) Men 1,761 21.7 8.7§ RR 1.35 (0.80–2.25) — 5.0 3.7
Women 674 11.4 8.7§ RR 4.98 (2.23–11.13) — 11.7 2.4
Iso et al., 2007 (111) Men 3,813 — 18.3¶ HR 1.90 (1.30–2.80) 2.00 (1.30–3.10) — —
Women 5,646 — 18.3¶ HR 1.40 (1.00–2.10) 1.50 (1.00–2.30) — —
Kokubo et al., 2008 (81) Men 2,492 18.0 — HR 1.52 (0.99–2.34) 1.58 (1.02–2.43) 6.5 4.0
Women 2,840 20.7 — HR 1.70 (1.09–2.64) 1.62 (1.02–2.58) 6.0 2.5
Koren-Morag et al., 2005 (112) Pts with CAD without T2DM 10,784 34.3 8.1 RR 1.44 (1.18–1.76) — 4.3 3.0
Men with CAD without T2DM 8,844 — 8.1 RR 1.31 (1.05–1.64) — 4.2 3.2
Women with CAD without T2DM 1,903 — 8.1 RR 2.09 (1.28–3.42) — 4.8 2.3
Kurl et al., 2006 (113) Men without T2DM 1,264 9.0 14.3§ RR 2.00 (1.01–3.95) 2.39 (1.17–4.89) — —
Ninomiya et al., 2007 (82) Men 1,050 20.6 14.0 HR 2.04 (1.33–3.14) 1.92 (1.23–2.98) 14.4 7.6
Women 1,402 29.9 14.0 HR 1.43 (0.99–2.08) 1.50 (1.03–2.19) 11.9 6.6
Song et al., 2007 (84) Women with BMI 25 kg/m2 13,256 4.3 10.0¶ RR 1.35 (0.74–2.45) 1.24 (0.64–2.39) 2.1 1.0
Women with BMI 25–29.9 kg/m2 7,834 4.3 10.0¶ RR 2.07 (1.23–3.47) — 1.7 0.8
Women with BMI 30 kg/m2 4,266 4.3 10.0¶ RR 1.79 (0.96–3.32) — 1.3 0.8
Takahashi et al., 2007 (13) Women without T2DM 726 1.1 6.4§ RR — 23.1 (2.7–19.6) — —
Takeuchi et al., 2005 (85) Men 780 25.3 6.0 RR — 1.61 (1.26–2.06) — —
Wannamethee et al., 2005 (114) Men 5,228 25.5 20.0 RR 1.51 (1.20–1.91) — 7.6 5.0
(continued on next page)
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ContinuedTable 5 Continued
First Author, Year (Ref. #)* Population n MetS (%) Follow-Up (yrs) Effect Measure
Risk of Stroke† (95% CI) Stroke (%)
Least Adjusted Most Adjusted MetS Group Non-MetS Group
Revised NCEP definition**
Nilsson et al., 2008 (102) Pts without T2DM 5,047 20.7 10.7§ RR 2.47 (1.83–3.34) — 6.4 2.6
Men without T2DM 3,008 26.0 10.7§ RR 2.10 (1.39–3.18) — 7.0 3.3
Women without T2DM 2,039 17.0 10.7§ RR 2.71 (1.75–4.19) — 5.9 2.2
Noto et al., 2008 (66) General population 685 22.9 15.0 HR 1.44 (0.94–2.19) — 6.8 3.5
Qiao et al., 2009 (106) Men without CAD and T2DM 4,041 — 21.0 HR 1.13 (0.81–1.58) — — —
Women without CAD and T2DM 3,812 — 21.0 HR 2.08 (1.24–3.51) — — —
Rodriguez-Colon et al., 2009 (115) General population 14,993 39.0 9.0 RR 2.45 (1.96–3.08) 2.24 (1.78–2.82) 3.2 1.3
Men 6,732 39.0 9.0 RR 1.98 (1.47–2.67) 2.11 (1.56–2.85) 3.7 1.9
Women 8,261 39.0 9.0 RR 3.27 (2.29–4.67) 2.41 (1.69–3.49) 2.9 1.1
Simons et al., 2007 (68) Elderly men 1,233 31.1 16.0 HR 1.43 (1.07–1.92) 1.31 (0.96–1.77) 70.1 15.8
Elderly women 1,572 34.1 16.0 HR 1.53 (1.17–2.01) 1.37 (1.04–1.82) 17.0 12.2
Wang et al., 2008 (108) Elderly without T2DM 991 50.8 13.8¶ HR 1.52 (1.10–2.11) — — —
Wassink et al., 2008 (50) Pts with CV risk factor 3,196 50.1 3.2¶ HR 1.75 (1.15–2.66) 1.77 (1.14–2.75) — —
Pts with CV factor without T2DM 2,472 — 3.2¶ HR 1.88 (1.18–2.99) 1.96 (1.21–3.18) — —
Wild et al., 2009 (116) General population 762 34.7 15.0 RR 2.61 (1.52–4.48) — 4.2 11.0
Modified revised NCEP definition#
Chen et al., 2006 (109) Men 709 48.6 10.4§ HR 8.20 (2.00–34.30) — 8.9 0.7
Women 850 57.3 10.4§ HR 2.60 (0.60–11.30) — 6.8 0.6
*Studies are listed by category and then alphabetically by author. †Nonadjusted risk estimates and risk estimates adjusting exclusively for age and/or sex were classified as “least adjusted.” Risk estimates adjusting for any cardiovascular risk factor or component of the
metabolic syndrome (i.e., smoking, cholesterol, obesity) were classified as “most adjusted.” ‡The NCEP defines the metabolic syndrome as having 3 or more of the following 5 cardiovascular risk factors: 1) central obesity (waist circumference: men 102 cm; women 88
cm); 2) elevated triglycerides (150mg/dl); 3) diminished high-density lipoprotein (HDL) cholesterol (men40mg/dl; women50mg/dl); 4) hypertension (130/85mmHg); and 5) elevated fasting glucose (110mg/dl). §Mean follow-up. Maximum follow-up. ¶Median
follow-up. #The modified NCEP and modified revised NCEP definitions use measurements of BMI (typically BMI 30 kg/m2 or BMI 27 kg/m2 in Asian populations) to define central obesity. **The revised NCEP definition uses a lower cutoff for elevated fasting glucose
of 100 mg/dl.
Abbreviations as in Tables 1 and 2.
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ontraceptive use (22–24), and gestational diabetes (25).
Our results also suggest that the metabolic syndrome
aintains its prognostic value for cardiovascular outcomes
n the absence of type 2 diabetes mellitus. Some experts have
uggested that the reason the metabolic syndrome is asso-
iated with an increase in cardiovascular risk is because most
atients with the metabolic syndrome also have type 2
iabetes mellitus (8). However, after synthesizing the results
f studies conducted in patients without type 2 diabetes
ellitus, the metabolic syndrome remained associated with
high cardiovascular risk, ranging from RR: 1.62 (95% CI:
.31 to 2.01; I2  0%; 95% CI: 0% to 90%) for MI, to RR:
.86 (95% CI: 1.10 to 3.17; I2  89; 95% CI: 56% to 97%)
or stroke. The risk for all-cause mortality in patients
ithout type 2 diabetes mellitus (RR: 1.32; 95% CI: 0.65 to
.67; I2  87; 95% CI: 47% to 97%) was accompanied by a
ide and therefore inconclusive confidence interval because
his analysis involved only 2 studies (n  3,622 patients).
ore studies are needed to confirm whether or not the
etabolic syndrome is prognostic in this population.
Our systematic review allowed us to identify an important
ap in the literature. The prognostic importance of the
etabolic syndrome, compared with that of the sum of its
ndividual components (obesity, systemic hypertension, el-
vated fasting glucose, elevated triglycerides, and low HDL
holesterol), has repeatedly been challenged (8,26,27). In a
ohort study of 2,815 patients, the risk of CVD mortality
ssociated with the metabolic syndrome as defined by the
CEP definition (HR: 2.53; 95% CI: 1.74 to 3.67) was
imilar to the risk associated with impaired fasting glucose
HR: 2.87; 95% CI: 1.96 to 4.20) and systemic hypertension
HR: 1.71; 95% CI: 1.15 to 2.54) (28). Furthermore, in a
ystematic review of 7 clinical trials (n  3,459), the
etabolic syndrome as defined by the NCEP definition was
o longer an independent predictor of atherosclerotic plaque
rogression after adjustment for its individual components
29). Despite these studies, there remains debate as to
hether or not the metabolic syndrome provides a syner-
istic effect that increases its association with cardiovascular
isk. Of the 87 studies included in our systematic review,
nly 5 reported risk estimates that were adjusted for at least
component of the metabolic syndrome (Online Table 5).
f these 5 studies, 3 adjusted for obesity, 3 adjusted for
ystemic hypertension, and 1 adjusted for fasting glucose.
here is a need for prospective studies that investigate the
isk associated with the metabolic syndrome independent of
he risk of its individual components in order to establish
hether or not the metabolic syndrome adds any prognostic
ignificance.
Our results allow us to confirm the strong association of
he 2001 NCEP definition of the metabolic syndrome with
ardiovascular risk. Furthermore, to our knowledge, no
revious meta-analyses have been conducted to establish the
ardiovascular risk associated with the 2004 rNCEP defi-nition. We recommend that health care workers use theSu
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I2  81%; 95% CI: 72% to 88%. Abbreviations as in Figure 2.Figure 5 The Metabolic Syndrome and the Relative Risk for MI
I2  40%; 95% CI: 0% to 73%. Abbreviations as in Figure 2.
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atients who are at risk for cardiovascular events. There is
n urgent need to develop and implement prevention and
reatment strategies, such as lifestyle programs, diets, and
harmacotherapies to reduce the prevalence of the meta-
olic syndrome and its associated cardiovascular risk
30,31).
revious studies. Two previous meta-analyses, which in-
luded studies published prior to 2005, investigated the
ardiovascular risk associated with the metabolic syndrome
9,10). An additional 71 studies investigating the NCEP
nd rNCEP definitions have been published since the
onduct of these meta-analyses, and these studies were
ncluded in our meta-analysis (32). We also established
he cardiovascular risk associated with the rNCEP defi-
ition of the metabolic syndrome, which was only re-
eased in 2004 (7). Finally, we confirmed that there was
ittle variation in cardiovascular risk between the modi-
ed NCEP and rNCEP definitions compared with the
Figure 6 The Metabolic Syndrome and the Relative Risk for Str
I2  88%; 95% CI: 82% to 91%. Abbreviations as in Figures 2 and 3.riginal NCEP definition. vThe 2 previous meta-analyses concluded that the meta-
olic syndrome nearly doubled the risk of cardiovascular
vents. We obtained consistently higher point estimates for
ardiovascular outcomes (RR 2) and showed that the risk
or CVD, CVD mortality, and stroke exceeds that of
ll-cause mortality. However, there remains a need for
uture studies to investigate the cardiovascular risk associ-
ted with the metabolic syndrome after its individual com-
onents have been adjusted for.
tudy limitations. Our meta-analysis has a number of
otential limitations. The inclusion of observational cohort
tudies in our meta-analysis presented challenges beyond
hose typically encountered in meta-analyses of randomized
ontrolled trials. First, of the 87 studies included in our
aper, only 34 studies reported count data that we pooled.
he remaining 53 studies only reported risk estimates (RR
r HR), which were not included in our pooled analyses.
owever, we included these 53 studies in tables as part of
ur systematic review. Second, the length of follow-upokearied considerably between studies. However, in a sensi-
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September 28, 2010:1113–32 The Metabolic Syndrome and Cardiovascular Riskivity analysis, we stratified studies by the length of
ollow-up and found that studies with longer follow-up
imes had risk estimates that were similar to those in studies
ith shorter follow-up times. There was also some hetero-
eneity in baseline patient characteristics, such as the
nclusion of patients with atherosclerosis, systemic hyper-
ension, or a history of CVD. Due to the presence of
otential heterogeneity between studies, data were analyzed
sing random-effects models, which incorporate both
ithin- and between-study variability. In addition, we
onducted a sensitivity analysis in which we restricted our
nalyses to studies of subjects without systemic hyperten-
ion, atherosclerosis, or cardiovascular disease. The results
f these analyses are consistent with those of our primary
nalysis. A third potential limitation was the limited num-
er of studies available to estimate the cardiovascular risk
ssociated with the metabolic syndrome in our subgroup
nalyses of men, women, and patients without type 2
iabetes mellitus. We could not conduct meta-regression
nalyses to estimate the effect of these covariates on the
etabolic syndrome–cardiovascular risk association since
he number of studies investigating these subgroups was
mall. A fourth limitation includes the inherent assumptions
f meta-analysis. We were limited to data reported in
ublished articles and did not have access to individual
atient-level data. Access to patient-level data would have
een particularly helpful for our subgroup analyses. Fifth,
isual assessment of funnel plots suggests that mild publi-
ation bias may be present. Publication bias is an inherent
imitation to virtually all meta-analyses. Finally, our meta-
nalysis was limited to studies published in English. How-
ver, 5% of studies identified in our literature search were
ublished in a language other than English, and their
xclusion is unlikely to substantially affect the conclusions of
ur meta-analysis.
onclusions
he metabolic syndrome is associated with a 2-fold increase in
isk for CVD, CVD mortality, MI, and stroke, and a 1.5-fold
ncrease in risk for all-cause mortality. There is little variation
n risk between the NCEP and rNCEP definitions of the
etabolic syndrome. There is also little variation in risk for the
odified NCEP and rNCEP definitions compared with the
riginal NCEP definition. In addition, our results indicate that
atients with the metabolic syndrome, but without type 2
iabetes mellitus, are still at high risk for CVD mortality, MI,
nd stroke. We therefore suggest that the metabolic syndrome
oes not require type 2 diabetes mellitus in its definition in
rder to be closely associated with cardiovascular risk. Our
ystematic review identified an important gap in the literature;
tudies are needed to investigate whether or not the prognostic
ignificance of the metabolic syndrome exceeds the risk asso-
iated with the sum of its individual components. We recom-
end that health care workers use the metabolic syndrome todentify patients who are at particularly high risk for cardio-ascular complications. The prevention and reduction of the
etabolic syndrome is essential to reduce cardiovascular dis-
ase and to extend life in the adult population.
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